Skip To Content
Apr 4, 2016

A 30-year Partnership In Advancing The Science Of Vision

Sharon Colle Orson Moritz

The video was created by Uwe Rafael Braun, Director/Editor, Atomic Cartoons Inc., and was made possible thanks to the generous support of Rob Simmons, Director of Finance and Business Affairs, Atomic Cartoons Inc. Rob also volunteers his time and expertise on Fighting Blindness Canada Board of Directors. (Music CC licensing included on the YouTube site).

Four decades ago, a small group of families scattered across Canada living with retinal eye diseases came together to spur sight-saving research.

“Artificial vision and stem cell and gene therapies are no longer science fiction—they are a reality,” says Sharon Colle, President and CEO of Fighting Blindness Canada. “How did we get here? Three words: hope, belief and determination.”

For most of its existence, Fighting Blindness Canada has channeled that hope, belief and determination to vision scientists at UBC, renewing funding year-after-year for several investigators in the Department of Ophthalmology and Visual Sciences, donating a total of $2.8 million.

The first beneficiary of peer-reviewed funding by Fighting Blindness Canada at UBC was Robert Molday, who received a grant in 1986 to investigate the molecular basis of normal vision. At the time, his lab was the only one at UBC studying the genes and proteins involved in the visual system, and specifically in rod and cone photoreceptors.

As Dr. Molday, now Professor, Canada Research Chair in Vision and Macular Degeneration and Director of the Centre for Macular Research at UBC, learned more about the visual system with the support from Fighting Blindness Canada over the years, his focus shifted to identifying the genes and mutations that cause retinal degenerative diseases such as retinitis pigmentosa and Leber Congenital Amaurosis (LCA).

By 2008, he was a leader in the field of retinal gene therapy. At this time, the world’s first test of retinal gene therapy was conducted in patients with LCA linked to mutations in the RPE65 gene. Today, Dr. Molday continues to work on critical preclinical studies with the hopes that they will enable gene therapies for other retinal degenerative diseases, such as Stargardt disease.

“This represents the culmination of an incredible amount of research,” says Orson Moritz, an Associate Professor who was a student of Dr. Molday in the 1990s. “It illustrates that everything we had been working toward is ultimately possible, and all of those previous steps—identifying genes, determining their function, developing gene therapies, testing in animal models, and finally developing human therapies—were worthwhile.”

Dr. Moritz received his first new investigator fellowship from Fighting Blindness Canada when he launched his own lab at UBC in 2003. With ongoing support, he went on to explore the mechanisms of secondary cone degeneration and regeneration in retinitis pigmentosa. Bolstered by another grant from Fighting Blindness Canada, Dr. Moritz is currently investigating a synthetic compound called valproic acid as therapy for this inherited, degenerative eye disease.

Over the decades, the Department of Ophthalmology and Visual Sciences has grown to include more than 20 clinician-scientists with collaborators across UBC and internationally, all dedicated to advancing knowledge and applying new discoveries for the improvement of eye care.

FBC President & CEO, Sharon Colle, with Drs. Orson Moritz, Bob Molday and David Maberley of the University of British Columbia.

Today, Fighting Blindness Canada continues to provide support for the research of Dr. Moritz and other UBC scientists who are investigating novel approaches to prevent and treat blindness.

For example, Assistant Professor Mahyar Etminan demonstrated a statistical connection between oral fluoroquinolones (a type of antibiotic) and retinal detachment, informing a recent recommendation by Health Canada to change the warning label for these medications, widely used to treat bacterial infections.

Professor Kevin Gregory-Evans, the Julia Levy BC Leadership Chair in Macular Research, has received several grants from Fighting Blindness Canada to investigate new molecular approaches to treating common retinal diseases.

Also with FBC’s support, Professor Cheryl Gregory-Evans is developing a drug administered by eye drop, Ataluren, to preserve sight by fixing genetic mutations that cause certain inherited eye disorders. Ataluren is currently in clinical trials for the nonsense mutation that causes the rare birth defect of aniridia. She is also testing this drug to see if it can repair LCA and Usher’s syndrome, in collaboration with Dr. Kevin Gregory-Evans. Ultimately, they aim to pursue a personalized medicine approach that uses a patient’s stem cells to determine whether the drug will restore this patient’s vision.

“Fighting Blindness Canada has been an incredible advocate and champion for Canadians with vision loss, and we are proud to have them as partners in our fight against blindness,” said David Maberley, Professor and Head of the UBC Department of Ophthalmology and Visual Sciences yesterday at an event at the Eye Care Centre to acknowledge FBC’s support. “Our progress toward creative new treatments for retinal diseases will continue to flourish thanks to the commitment of Fighting Blindness Canada and the generosity of its donors.”

Story contributed by staff at the University of British Columbia. Photo caption: Sharon Colle, President and CEO of Fighting Blindness Canada and Orson Moritz, Associate Professor in the Department of Ophthalmology and Visual Sciences. Photo credit: Don Erhardt.

Join the Fight!

Learn how your support is helping to bring a future without blindness into focus! Be the first to learn about the latest breakthroughs in vision research and events in your community by subscribing to our e-newsletter that lands in inboxes the beginning of each month.

I have read and accepted the privacy policy